GAITHERSBURG, Md., April 8, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the Goldman Sachs Recovery Inoculated: The Current Outlook for COVID-19 Vaccines, Treatments, Testing and the Economy virtual conference. Novavax' COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

Fireside chat details:
Date:	Tuesday, April 13, 2021
Time:	2:30 – 3:20 p.m. Eastern Time (ET)
Panel title:	COVID-19 Vaccines – Staying Ahead of the Curve
Novavax participant:	More on Marylandian Maryland: NEWS RELEASE: Caroline County Control Area Released JGCMGS Details Architecture to Safeguard Assets From Unauthorized Phishing Scams 21 Days: The Malta Deadline That Could Redraw the Finnish Online Casino Map JEGS Launches Modern, Secure Payments Powered by PhaseZero.ai U.S. Government Contracts in Excess of 38 Million Secured Through Partner, Establishing Multi-Year Defense Revenue Platform Through 2032: $BLIS Vivek Shinde, M.D., M.P.H., Vice President, Clinical Development
	This event is open to Goldman Sachs clients.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

More on Marylandian

• New Report Reveals Surprising Trends in Ohio Airport Accidents
• Why Your Berberine Failed: RevGenetics Unveils the Absorption Gap Solution
• WCC Kitchens and Cabinets Featured on Selling Houses Australia
• Cat Hunt Simulator : Burrow & Pounce Lands on the App Store
• Shincheonji Marks 42nd Anniversary: From a Basement to a Denomination Growing by Tens of Thousands Annually

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
[email protected]

Solebury Trout
Jennifer Porcelli | 646-378-2962
[email protected]

Media
Laura Keenan | 410-419-5755
Amy Speak | 617-420-2461
[email protected]

SOURCE Novavax, Inc.

Related Links

http://www.novavax.com

---

Show All News | Report Violation